{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["110(3)"],"submitter":["Kragh N"],"funding":["Swedish Orphan Biovitrum"],"pubmed_abstract":["<h4>Introduction</h4>The economic and clinical burden of haemophilia A is high. Primary prophylaxis with factor VIII replacement therapy is the recognised standard of care, but the emergence of non-factor therapies, such as emicizumab, is extending treatment options for people with haemophilia A.<h4>Aim</h4>There are currently no direct comparisons of efficacy or cost between recombinant factor FVIII Fc-fusion protein efmoroctocog alfa (a recombinant factor FVIII Fc-fusion protein referred to herein as rFVIIIFc) and emicizumab; therefore, a cost-effectiveness model was developed to compare prophylactic treatment with rFVIIIFc versus emicizumab in patients with haemophilia A without inhibitors in the UK.<h4>Methods</h4>The cost-effectiveness model was based on a matching-adjusted indirect c"],"journal":["European journal of haematology"],"pagination":["262-270"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10107896"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK."],"pmcid":["PMC10107896"],"pubmed_authors":["Pochopien M","Aballea S","Tytula A","Kragh N","Toumi M","Bystricka L","Fatoye F","Nazir J","Hakimi Z"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.","description":"<h4>Introduction</h4>The economic and clinical burden of haemophilia A is high. Primary prophylaxis with factor VIII replacement therapy is the recognised standard of care, but the emergence of non-factor therapies, such as emicizumab, is extending treatment options for people with haemophilia A.<h4>Aim</h4>There are currently no direct comparisons of efficacy or cost between recombinant factor FVIII Fc-fusion protein efmoroctocog alfa (a recombinant factor FVIII Fc-fusion protein referred to herein as rFVIIIFc) and emicizumab; therefore, a cost-effectiveness model was developed to compare prophylactic treatment with rFVIIIFc versus emicizumab in patients with haemophilia A without inhibitors in the UK.<h4>Methods</h4>The cost-effectiveness model was based on a matching-adjusted indirect c","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-04T20:46:02.994Z","creation":"2025-04-04T20:46:02.994Z"},"accession":"S-EPMC10107896","cross_references":{"pubmed":["36398467"],"doi":["10.1111/ejh.13901"]}}